Ginsenoside Rg3 improves atezolizumab immune checkpoint therapy in triple-negative breast cancer by targeting FUT8-mediated PD-L1 N-glycosylation

Meng Tian

doi:10.1016/j.phymed.2026.158272

Direct glycoprotein-specific platelet autoantibodies detected in a majority of patients with persistent chemotherapy-induced thrombocytopenia

2026-07-10

0

PRE

AI

A

Andrew B. Song

B

Brian R. Curtis

H

Hanny Al‐Samkari *

DOI：10.1016/j.jtha.2026.06.042

Original

Original request for help

Save

Abstract

En 中文

Chemotherapy-induced thrombocytopenia (CIT) is common in patients with solid tumors and often necessitates chemotherapy dose reduction or delay, compromising cancer outcomes. Persistent CIT, defined by inadequate platelet recovery between cycles, is typically attributed to cumulative myelosuppression, although emerging data suggest that immune dysregulation may also contribute. Platelet autoantibody (PA) testing, well studied in immune thrombocytopenia (ITP), has not been systematically examined in persistent CIT.

Direct glycoprotein-specific platelet autoantibodies detected in a majority of patients with persistent chemotherapy-induced thrombocytopenia

Abstract

Journal

Organization

Cited Papers

Citing Papers